Neurobiological Technologies Announces FDA Agreement To Consolidate Viprinex Phase 3 Trials Accelerating Time To Pivotal Data Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that following a meeting with the U.S. Food and Drug Administration to discuss the Viprinex(TM) (ancrod) Phase 3 clinical program for acute ischemic stroke, the company plans to consolidate and analyze data from its two concurrently running double-blind clinical trials into a single Phase 3 pivotal trial. This new plan will accelerate the timing of the trial's efficacy and safety data to mid-2009.
Source: www.medicalnewstoday.comNew Data Shows Abbott's Bioabsorbable Drug Eluting Stent Is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels Abbott (NYSE: ABT) announced two-year data from 30 patients in its ABSORB clinical trial, demonstrating that its bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years, leaving behind blood vessels that appeared to move and function similar to unstented arteries.
Source: www.medicalnewstoday.comDiscovery Of Baldness Gene: 1 In 7 Men At Risk Researchers at McGill University, King's College London and GlaxoSmithKline Inc. have identified two genetic variants in caucasians that together produce an astounding sevenfold increase in the risk of male pattern baldness. Their results were published Oct. 12 in the journal Nature Genetics. About a third of all men are affected by male pattern baldness by age 45.
Source: www.medicalnewstoday.comPeregrine Pharmaceuticals' Anti-PS Technology Platform To Be Discussed At AIDS Vaccine 2008 Conference Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, reported the company's anti-phosphatidylserine (anti-PS) technology platform will be discussed in scientific sessions at the AIDS Vaccine 2008 conference in Cape Town, South Africa.
Source: www.medicalnewstoday.comExpanding Premature Infant Follow-Up Care Research With 5 New MedImmune Fellowship Grants Five neonatology fellows have been awarded grants designed to stimulate interest and research in the area of follow-up care of the premature infant as part of MedImmune's Fellowship Program. The grants, which underscore MedImmune's commitment to expanding research within pediatric
medicine, will provide each recipient's institution a $35,000 grant, totaling $175,000 in research funding.
Source: www.medicalnewstoday.comFDA Approves Bayer HealthCare's Kogenate(R) FS Treatment For Routine Prophylaxis In Children With Hemophilia A Bayer
HealthCare LLC announced that the U.S. Food and Drug Administration (FDA) has approved routine prophylaxis with Kogenate(R) FS Antihemophilic Factor (Recombinant) to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 AM
